{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:47:53Z","timestamp":1763038073730,"version":"3.40.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bmcl.2025.130221","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T14:11:50Z","timestamp":1744035110000},"page":"130221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non\u2011zinc binding mode"],"prefix":"10.1016","volume":"123","author":[{"given":"Rainer E.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Satz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kuratli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Hunziker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizio","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Hert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Ullmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus G.","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 M.","family":"Alker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Hochstrasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Binder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130221_bb0005","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1021\/acs.jmedchem.5b01599","article-title":"Development of autotaxin inhibitors: an overview of the patent and primary literature","volume":"59","author":"Castagna","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/13543776.2017.1323331","article-title":"Autotaxin inhibitors: a patent review (2012-2016)","volume":"27","author":"Nikolaou","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2025.130221_bb0015","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/cr2003213","article-title":"Chemical evolution of autotaxin inhibitors","volume":"112","author":"Albers","year":"2012","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130221_bb0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11302-005-5303-4","article-title":"Modulation of purinergic signaling by NPP-type ectophosphodiesterases","volume":"2","author":"Stefan","year":"2006","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.bmcl.2025.130221_bb0025","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1194\/jlr.R046391","article-title":"Autotaxin: structure-function and signaling","volume":"55","author":"Perrakis","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bmcl.2025.130221_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvq052","article-title":"Autotaxin - an LPA producing enzyme with diverse functions","volume":"148","author":"Nakanaga","year":"2010","journal-title":"J Biochem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0035","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1021\/acsmedchemlett.7b00312","article-title":"Discovery of BI-2545: a novel autotaxin inhibitor that significantly reduces LPA levels in vivo","volume":"8","author":"Kuttruff","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130221_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117374","article-title":"Recent research advances in ATX inhibitors: an overview of primary literature","volume":"90","author":"Zhang","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/med.21551","article-title":"Development and therapeutic potential of autotaxin small molecule inhibitors: from bench to advanced clinical trials","volume":"39","author":"Matralis","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2025.130221_bb0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.R046458","article-title":"LPA receptor signaling: pharmacology, physiology, and pathophysiology","volume":"55","author":"Yung","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bmcl.2025.130221_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbalip.2008.06.005","article-title":"Two pathways for lysophosphatidic acid production","volume":"1781","author":"Aoki","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmcl.2025.130221_bb0060","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/acs.jmedchem.7b00032","volume":"60","author":"Desroy","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.bmcl.2025.130221_bb0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1165\/rcmb.2012-0004OC","article-title":"Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis","volume":"47","author":"Oikonomou","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130221_bb0075","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cca.2012.07.014","article-title":"Autotaxin in liver fibrosis","volume":"413","author":"Ikeda","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bmcl.2025.130221_bb0080","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13543784.2024.2305126","article-title":"Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis","volume":"33","author":"Simonetti","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmcl.2025.130221_bb0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MCP.0000000000001099","article-title":"The future of clinical trials in idiopathic pulmonary fibrosis","volume":"30","author":"Spagnolo","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.bmcl.2025.130221_bb0090","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1084\/jem.20112012","article-title":"Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis","volume":"209","author":"Nikitopoulou","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2025.130221_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699535","article-title":"Synthesis, characterization, and in vivo evaluation of a novel potent autotaxin-inhibitor","volume":"12","author":"Hunziker","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2025.130221_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042627","article-title":"Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure","volume":"7","author":"Iyer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2025.130221_bb0105","first-page":"9173090\/1","article-title":"Autotaxin-lysophosphatidic acid: from inflammation to cancer development","author":"Valdes-Rives","year":"2017","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.bmcl.2025.130221_bb0110","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/ijms21165938","article-title":"Role of adipose tissue-derived autotaxin, lysophosphatidate signaling, and inflammation in the progression and treatment of breast cancer","volume":"21","author":"Brindley","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2025.130221_bb0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers10030073","article-title":"Coming of age for autotaxin and lysophosphatidate signaling: clinical applications for preventing, detecting and targeting tumor-promoting inflammation","volume":"10","author":"Benesch","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2025.130221_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102327","article-title":"Autotaxin and chronic inflammatory diseases","volume":"104","author":"Magkrioti","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bmcl.2025.130221_bb0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/acsmedchemlett.1c00211","article-title":"Discovery of potent selective nonzinc binding autotaxin inhibitor BIO-32546","volume":"12","author":"Ma","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130221_bb0130","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1039\/C6MD00221H","article-title":"Analysis of the productivity of DNA encoded libraries","volume":"7","author":"Eidam","year":"2016","journal-title":"Med Chem Commun"},{"key":"10.1016\/j.bmcl.2025.130221_bb0135","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1021\/jm049609r","article-title":"Synthesis, structure\u2212activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPAR\u03b3, and inhibitors of autotaxin","volume":"48","author":"Durgam","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/acsptsci.0c00076","article-title":"Metabolic efficacy of phosphate prodrugs and the remdesivir paradigm","volume":"3","author":"Wiemer","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.bmcl.2025.130221_bb0145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.110.165845","article-title":"A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation","volume":"334","author":"Gierse","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2025.130221_bb0150","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nchembio.211","article-title":"Design, synthesis and selection of DNA-encoded small-molecule libraries","volume":"5","author":"Clark","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130221_bb0155","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1021\/acschembio.5b00378","article-title":"DNA encoded library selections and insights provided by computational simulations","volume":"10","author":"Satz","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2025.130221_bb0160","unstructured":"logD values were measured spectrophotometrically at pH = 7.4 in an 1-octanol \/ 50 mM TAPSO buffer system containing 5% (v\/v) DMSO."},{"key":"10.1016\/j.bmcl.2025.130221_bb0165","unstructured":"Aqueous solubility was measured from lyophilized DMSO stock solutions spectrophotometrically at pH = 6.5 in a 50 mM phosphate buffer (Lyophilisation Solubility Assay, Lysa)."},{"key":"10.1016\/j.bmcl.2025.130221_bb0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"low: Pe < 0.1, medium: 0.1 < Pe < 1.0, high: Pe > 1.0. See: Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes","volume":"41","author":"Pampa (Parallel Artificial Membrane Permeation Assay)","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0175","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist's guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0180","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ejmech.2018.08.081","article-title":"HDAC3 is a potential validated target for cancer: an overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR\/QSAR\/QAAR approaches","volume":"157","author":"Adhikari","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112845","article-title":"Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: comparative SAR\/QSAR assessment on steroidal aromatase inhibitors","volume":"208","author":"Adhikari","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107481","article-title":"Pharmacophore-based virtual screening, 3D QSAR, docking, ADMET, and MD simulation studies: an in silico perspective for the identification of new potential HDAC3 inhibitors","volume":"166","author":"Lanka","year":"2023","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.bmcl.2025.130221_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108051","article-title":"An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches","volume":"110","author":"Banerjee","year":"2024","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0200","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2174\/0929867321666140916122628","article-title":"Idiosyncratic drug hepatotoxicity: strategy for prevention and proposed mechanism","volume":"22","author":"Ikeda","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2025.130221_bb0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1872-0854(06)01005-8","article-title":"Idiosyncratic drug reactions: clinical evidence for mechanistic hypotheses","volume":"1","author":"Uetrecht","year":"2006","journal-title":"Adv Mol Tox"},{"author":"Hert","key":"10.1016\/j.bmcl.2025.130221_bb0210"},{"key":"10.1016\/j.bmcl.2025.130221_bb0215","unstructured":"CCDC 2409127 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk\/data_request\/cif."}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:02:16Z","timestamp":1745528536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"alternative-id":["S0960894X25001301"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130221","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non\u2011zinc binding mode","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130221"}}